The effect of recombinant human lactoferrin on growth and the antibiotic susceptibility of the cystic fibrosis pathogen Burkholderia cepacia complex when cultured planktonically or as biofilms

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 546-554

  Caraher, Emma M ^a   Gumulapurapu, Kiranmai ^a   Taggart, Clifford C ^b   Murphy, Philip ^c,d   McClean, Siobhán ^a   Callaghan, Máire ^a  

^a DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Bacterial biofilms; Biofilm inhibitory concentrations; Rifampicin

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; HUMAN RECOMBINANT LACTOFERRIN; LACTOFERRIN; RIFAMPICIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOPLANKTON; BACTERIOSTASIS; BACTERIUM CULTURE; BIOFILM; BURKHOLDERIA; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA DOLOSA; BURKHOLDERIA MULTIVORANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLATE COUNT; SPECTROPHOTOMETRY;

BIOFILMS; BURKHOLDERIA CEPACIA COMPLEX; COLONY COUNT, MICROBIAL; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; LACTOFERRIN; MICROBIAL SENSITIVITY TESTS; RECOMBINANT PROTEINS;

EID: 34548118785     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm222     Document Type: Article

References (35)

1. Isles A, Maclusky I, Corey M et al. Pseudomonas cepacia infection in cystic fibrosis: An emerging problem. J Pediatr 1984; 104 206-10.
2. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia capacia complex, Nat Rev Microbiol 2005; 3: 144-56.
3. LiPuma JJ, Spilker T, Gill LH et al. Disproportionate distribution of Burkholderia cepacia complex species-and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 2001; 164 92-6.
4. Speert DP, Henry D, Vandamme P et al. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis 2002; 8: 181-7.
5. Chemish RN, Aaron SD. Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med 2003; 9: 509-15.
6. Schwab U, Leigh M, Ribeiro C et al. Patterns of epithelial cell invasion by different species of the Burkholderia capacia complex in well-differentiated human airway epithelia. Infect Immun 2002; 70: 4547-55.
7. Burns JL, Jonas M, Chi EY et al. Invasion of respiratory epithelial cells by. Burkholderia (Pseudomonas) cepacia. Infect Immun 1996; 64: 4054-9.
8. Harbitz O, Jenssen AO, Smidsrod O. Lysozyme and lactoferrin in sputum from patients with chronic obstructive lung disease. Eur J Respir Dis 1984 65: 512-20.
9. Jacquot J, Tournier JM, Carmona TG et al. Proteins of bronchial secretions in mucoviscidosis. Role of infection. Bull Eur Physiopathol Respir 1983; 19: 453-8.
10. Bullen JJ. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. Proc R Soc Med 1972; 65: 1086.
11. Elass-Rochard E, Roseanu A, Legrand D et al. Lactoferrin-lipopolsaccharide interacton: Involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. Biochem J 1995; 312: 839-45.
12. Ellison RT, 3rd. The effects of lactoferrin on gram-negative bacteria. Adv Exp Med Biol 1994; 357: 71-90.
13. Dial EJ, Lichtenberger LM. Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol 2002; 80: 113-7.
14. Longhi C, Conte MP, Seganti L et al. Influence of lactoferrin on the entry process of Escherichia coli HB101 (pRI203) in HeLa cells. Med Microbiol Immunol 1993; 182: 25-35.
15. Conte MP, Longhi C, Petrone G et al. The anti-invasive effect of bovine lactoferrin requires an interaction with surface proteins of Listeria monocytogenes. Int J Immunopathol Pharmacol 1999; 12: 149-55.
16. Singh PK, Parsek MR, Greenberg EP et al. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417: 552-5.
17. Rogan MP, Taggart CC, Greene CM et al. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis 2004; 190: 1245-53.
18. Naldu AS, Arnold RR. Lactoferrin interaction with salmonellae potentiates antibiotic susceptibility in vitro. Diagn Microbiol Infect Dis 1994; 20: 69-75.
19. 2+. J Gen Microbiol 1990; 136: 1437-46.
20. Qamruddin AO, Alkawash MA, Soothill JS. Antibiotic susceptibility of Stenotrophomonas maltophilla in the presence of lactoferrin. Antimicrob Agents Chemother 2005; 49: 4425-6.
21. Alkawash M, Head M, Alshami I et al. The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains. J Antimicrob Chemother 1999; 44: 385-7.
22. Kalish LA, Waltz DA, Dovey M et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2005; 173: 421-5.
23. Caraher E, Duff C, Mullen T et al. Invasion and biofilm formation of Burkholderia dolosa is comparable with Burkholderia cenocepacia and Burkholderia multivorans. J Cyst Fibros 2007; 6: 49-56.
24. Caraher E, Reynolds G, Murphy P et al. Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro, Eur J Clin Microbiol Infect Dis 2007; 26: 213-6.
25. Coenye T, Vandamme P, LiPuma JJ et al. Updated version of the Burkholderia cepacia complex experimental strain panel. J Clin Microbiol 2003; 41: 2797-8.
26. Mahenthiralingam E, Coenye T, Chung JW et al. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol 2000; 38: 910-3.
27. Henry DA, Campbell ME, LiPuma JJ et al. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol 1997; 35 614-9.
28. O'Toole GA, Kolter R. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: A genetic analysis. Mol Microbiol 1998; 28: 449-61.
29. Petschow BW, Talbott RD. Response of bifidobacterium species to growth promoters in human and cow milk. Pediatr Res 1991; 29: 208-13.
30. Jones AM, Dodd ME, Govan JR et al. Burkholderia cenocepacia and Burkholderia multivorans: Influence on survival in cystic fibrosis. Thorax 2004; 59: 948-51.
31. Berlutti F, Morea C, Battistoni A et al. Iron availability influences aggregation, biofilm, adhesion and invasion of Pseudomonas aeruginosa and Burkholderia cenocepacia. Int J Immunopathol Pharmacol 2005; 18: 661-70.
32. Aaron SD, Ferris W, Ramoter K et al. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa Isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 2002; 40: 4172-9.
33. Moskowitz SM, Foster JM, Emerson J et al. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42: 1915-22.
34. Bagge N, Schuster M, Hentzer M et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and β-lactamase and alginate production. Antimicrob Agents Chemother 2004; 48: 1175-87.
35. Saginur R, Stdenis M, Ferris W et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006; 50: 55-61.